Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.

The Journal of antimicrobial chemotherapy - 1 Oct 2014

Charpentier Charlotte, Choquet Marion, Joly Véronique, Yeni Patrick, Visseaux Benoit, Caseris Marion, Brun-Vézinet Françoise, Yazdanpanah Yazdan, Peytavin Gilles, Descamps Diane, Landman Roland

Abstract excerpt

OBJECTIVES: To describe the virological and pharmacological outcomes of three different recommended once-daily first-line regimens in a cross-sectional analysis within an observational cohort using ultra-sensitive HIV quantification. PATIENTS AND METHODS: We enrolled all HIV-1-infected patients who initiated tenofovir/emtricitabine with efavirenz, darunavir/ritonavir or atazanavir/ritonavir as a first-line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Sectional Studies

Share to Drug Monitoring

Share to Drug Resistance, Viral

Share to HIV Infections

Share to Viral Load

Source

Identifiers

PMID: 24948705
DOI: 10.1093/jac/dku211

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.PMID 24948705Read ↗

Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.Semantic proximity Read ↗

Improved Prediction of Salvage Antiretroviral Therapy Outcomes Using Ultrasensitive HIV-1 Drug Resistance TestingSemantic proximity Read ↗

Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.Semantic proximity Read ↗

Virologic and immunologic effectiveness of darunavir-based salvage therapy in HIV-1-infected adults in a Brazilian clinical practice setting: results of a multicenter and retrospective cohort study.Semantic proximity Read ↗

Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment.Semantic proximity Read ↗

Clinical Outcomes Following the Use of Archived Proviral HIV-1 DNA Genotype to Guide Antiretroviral Therapy AdjustmentSemantic proximity Read ↗

Impact of pre-therapy viral load on virological response to modern first-line HAART.Semantic proximity Read ↗

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).Semantic proximity Read ↗

Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up.Semantic proximity Read ↗

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.Semantic proximity Read ↗

Class-sparing regimens for initial treatment of HIV-1 infection.Semantic proximity Read ↗

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.